DK2331129T3 - Sammensætning omfattende et kompleksbundet (m)rna og et nøgen mrna for at tilvejebringe eller øge et immunstimulerende respons i et pattedyr og anvendelser deraf - Google Patents
Sammensætning omfattende et kompleksbundet (m)rna og et nøgen mrna for at tilvejebringe eller øge et immunstimulerende respons i et pattedyr og anvendelser derafInfo
- Publication number
- DK2331129T3 DK2331129T3 DK09736823.7T DK09736823T DK2331129T3 DK 2331129 T3 DK2331129 T3 DK 2331129T3 DK 09736823 T DK09736823 T DK 09736823T DK 2331129 T3 DK2331129 T3 DK 2331129T3
- Authority
- DK
- Denmark
- Prior art keywords
- mammal
- rna
- enhance
- complex
- composition
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001132—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
- A61K39/001159—Matrix metalloproteinases [MMP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
- A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2008/008304 WO2010037408A1 (en) | 2008-09-30 | 2008-09-30 | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
PCT/EP2009/007032 WO2010037539A1 (en) | 2008-09-30 | 2009-09-30 | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2331129T3 true DK2331129T3 (da) | 2014-08-25 |
Family
ID=40685915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09736823.7T DK2331129T3 (da) | 2008-09-30 | 2009-09-30 | Sammensætning omfattende et kompleksbundet (m)rna og et nøgen mrna for at tilvejebringe eller øge et immunstimulerende respons i et pattedyr og anvendelser deraf |
Country Status (17)
Country | Link |
---|---|
US (3) | US9572874B2 (da) |
EP (2) | EP2762165B1 (da) |
JP (2) | JP5859853B2 (da) |
KR (1) | KR101343043B1 (da) |
CN (1) | CN102123733B (da) |
AU (1) | AU2009300113B2 (da) |
BR (1) | BRPI0915844B1 (da) |
CA (1) | CA2730261C (da) |
DK (1) | DK2331129T3 (da) |
ES (1) | ES2502915T3 (da) |
HR (1) | HRP20140763T1 (da) |
MX (1) | MX2010013071A (da) |
PL (1) | PL2331129T3 (da) |
PT (1) | PT2331129E (da) |
RU (1) | RU2545756C2 (da) |
SI (1) | SI2331129T1 (da) |
WO (2) | WO2010037408A1 (da) |
Families Citing this family (307)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
DE102005023170A1 (de) * | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
CA2646329C (en) | 2006-03-20 | 2018-07-03 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
WO2007147265A1 (en) | 2006-06-23 | 2007-12-27 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
AU2007280690C1 (en) | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
ES2552842T3 (es) | 2007-02-19 | 2015-12-02 | Marine Polymer Technologies, Inc. | Composiciones hemostáticas y regímenes terapéuticos |
CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
EP2548960B1 (en) * | 2008-01-31 | 2018-01-31 | CureVac AG | Nucleic acids comprising formula (nugixmgnv)a and derivatives thereof as an immunostimulating agents/adjuvant |
US8475785B2 (en) | 2008-03-03 | 2013-07-02 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
EP3130674B1 (en) | 2008-11-03 | 2020-07-08 | ADC Therapeutics SA | Antibodies that specifically block the biological activity of a tumor antigen |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
DK3338765T3 (da) | 2009-12-01 | 2019-03-04 | Translate Bio Inc | Steroidderivat til leveringen af mrna i humangenetiske sygdomme |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
EP2338520A1 (de) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Konjugat mit Zielfindungsligand und dessen Verwendung |
CA2791025A1 (en) * | 2010-02-25 | 2011-09-01 | Duke University | Method of inducing the production of protective anti-hiv-1 antibodies |
CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
BR112013004879A2 (pt) | 2010-08-31 | 2018-04-24 | Novartis Ag | lipossomas pequenos para entrega de rna que codifica imunogénio |
HUE058667T2 (hu) | 2010-08-31 | 2022-09-28 | Glaxosmithkline Biologicals Sa | Pegilált liposzómák immunogént kódoló RNS szállítására |
EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
PL3536703T3 (pl) * | 2010-11-12 | 2021-10-25 | The Trustees Of The University Of Pennsylvania | Konsensusowe antygeny gruczołu krokowego, kodujące je cząsteczki kwasu nukleinowego i ich zastosowania |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
EP2680881B1 (en) | 2011-03-02 | 2017-04-05 | CureVac AG | Vaccination in elderly patients |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
EA038979B1 (ru) | 2011-03-31 | 2021-11-17 | Адс Терапьютикс Са | Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты |
NZ730355A (en) | 2011-05-24 | 2022-10-28 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Individualized vaccines for cancer |
EP2714071B1 (en) | 2011-05-24 | 2019-07-10 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
ME03491B (me) | 2011-06-08 | 2020-01-20 | Translate Bio Inc | Kompozicije lipidnih nanočestica i postupci za isporuku irnk |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
WO2013012875A2 (en) | 2011-07-18 | 2013-01-24 | Mount Sinai School Of Medicine | Bacterial rnas as vaccine adjuvants |
CN102973950B (zh) * | 2011-09-06 | 2015-05-27 | 四川百利药业有限责任公司 | Prame、wt1双价肿瘤dna疫苗 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP2755986A4 (en) * | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MODIFIED NUCLEIC ACIDS AND METHODS OF USE |
HUE057725T2 (hu) | 2011-10-03 | 2022-06-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
CN102344974A (zh) * | 2011-11-22 | 2012-02-08 | 王旋 | 鸡传染性贫血病毒lamp检测试剂盒及其检测方法 |
HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
CN103184221B (zh) * | 2011-12-30 | 2016-03-30 | 复旦大学 | 核开关aac及其在制备抗生素中的应用 |
PL2802351T3 (pl) | 2012-01-09 | 2019-11-29 | Adc Therapeutics Sa | Środki do leczenia potrójnie negatywnego raka piersi |
EP3838294A1 (en) | 2012-01-31 | 2021-06-23 | CureVac AG | Negatively charged nucleic acid comprising complexes for immunostimulation |
WO2013113325A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
CN102526725B (zh) * | 2012-02-22 | 2013-09-04 | 中国医学科学院医学生物学研究所 | Atp、氢氧化铝复合佐剂及含有该复合佐剂的疫苗 |
US9709577B2 (en) * | 2012-03-23 | 2017-07-18 | Laboratorios Del Dr. Esteve S.A. | Method for monitoring HIV specific T cell responses |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
PL2830593T3 (pl) * | 2012-03-26 | 2019-08-30 | Biontech Rna Pharmaceuticals Gmbh | Preparat rna do immunoterapii |
CN108929880A (zh) | 2012-03-27 | 2018-12-04 | 库瑞瓦格股份公司 | 包含5′toputr的人工核酸分子 |
CA2866955A1 (en) | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules |
CA2859452C (en) | 2012-03-27 | 2021-12-21 | Curevac Gmbh | Artificial nucleic acid molecules for improved protein or peptide expression |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
AU2013243947A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013164754A2 (en) * | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
US8735359B2 (en) * | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
WO2013185069A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mrna to non-lung target cells |
DK2858677T3 (da) * | 2012-06-08 | 2020-08-31 | Ethris Gmbh | Pulmonær levering af messenger rna |
KR20150033703A (ko) | 2012-06-27 | 2015-04-01 | 오르반 바이오테크 엘엘씨 | 당뇨병 치료를 위한 ctla4 융합 단백질 |
TWI677350B (zh) * | 2012-09-25 | 2019-11-21 | 美商健臻公司 | 治療強直性肌失養症之經胜肽連結之嗎啉基反義寡核苷酸 |
ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
AU2014220957A1 (en) | 2013-02-22 | 2015-07-30 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
EP3292873B1 (en) | 2013-02-22 | 2019-05-01 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
LT2970456T (lt) | 2013-03-14 | 2021-08-10 | Translate Bio, Inc. | Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui |
LT2968586T (lt) | 2013-03-14 | 2018-11-26 | Translate Bio, Inc. | Cft mrnr kompozicijos bei su jomis susiję būdai ir panaudojimai |
WO2014144196A1 (en) | 2013-03-15 | 2014-09-18 | Shire Human Genetic Therapies, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
WO2014152030A1 (en) * | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
CN103160608A (zh) * | 2013-04-11 | 2013-06-19 | 中华人民共和国上海出入境检验检疫局 | 食品过敏原羽扇豆成分lamp现场快速检测方法 |
PL3019619T3 (pl) | 2013-07-11 | 2022-01-10 | Modernatx, Inc. | Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania |
EP3033113B1 (en) | 2013-08-13 | 2023-10-04 | Baylor College of Medicine | A novel plga-modified polyethylenimine self-assembly nanotechnology for nucleic acid and drug delivery |
AU2014310934B2 (en) | 2013-08-21 | 2019-09-12 | CureVac SE | Respiratory syncytial virus (RSV) vaccine |
EP3586871A3 (en) | 2013-08-21 | 2020-03-11 | CureVac AG | Respiratory syncytial virus (rsv) vaccine |
PE20160224A1 (es) * | 2013-08-21 | 2016-05-14 | Curevac Ag | Composicion y vacuna para tratar cancer de pulmon |
AU2014310931B2 (en) | 2013-08-21 | 2019-12-19 | CureVac SE | Rabies vaccine |
EP4043032A1 (en) | 2013-08-21 | 2022-08-17 | CureVac AG | Rabies vaccine |
RU2733424C2 (ru) | 2013-08-21 | 2020-10-01 | Куревак Аг | Способ повышения экспрессии кодируемых рнк белков |
WO2015024669A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
EP3046577A4 (en) * | 2013-09-20 | 2017-04-05 | Landegren, Nils | A novel autoantigen |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN112618732A (zh) | 2013-10-22 | 2021-04-09 | 夏尔人类遗传性治疗公司 | 用于递送信使rna的脂质制剂 |
WO2015065097A1 (ko) * | 2013-10-31 | 2015-05-07 | 에스케이텔레콤 주식회사 | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법 |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
JP6704850B2 (ja) | 2013-12-30 | 2020-06-03 | キュアバック アーゲー | 人工核酸分子 |
US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
EP3090053B1 (en) | 2013-12-30 | 2018-11-21 | CureVac AG | Artificial nucleic acid molecules |
AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
EP3590529A1 (en) | 2014-03-12 | 2020-01-08 | CureVac AG | Combination of vaccination and ox40 agonists |
EP3129050A2 (en) | 2014-04-01 | 2017-02-15 | CureVac AG | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
JP6557722B2 (ja) | 2014-05-30 | 2019-08-07 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 核酸の送達のための生分解性脂質 |
US10837039B2 (en) | 2014-06-10 | 2020-11-17 | Curevac Real Estate Gmbh | Methods and means for enhancing RNA production |
CN106795142B (zh) | 2014-06-24 | 2022-11-04 | 川斯勒佰尔公司 | 用于递送核酸的立体化学富集组合物 |
PL3766916T3 (pl) | 2014-06-25 | 2023-02-27 | Acuitas Therapeutics Inc. | Nowe lipidy i formulacje nanocząstek lipidowych do dostarczania kwasów nukleinowych |
CN104537150A (zh) * | 2014-12-01 | 2015-04-22 | 艾法能源工程股份有限公司 | 在pdms中对管支架材料的统计方法 |
PT4023755T (pt) | 2014-12-12 | 2023-07-05 | CureVac SE | Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína |
ES2658310T3 (es) | 2014-12-23 | 2018-03-09 | 4D Pharma Research Limited | Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación |
SI3193901T1 (en) | 2014-12-23 | 2018-06-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
EP3494982A1 (en) | 2014-12-30 | 2019-06-12 | CureVac AG | Artificial nucleic acid molecules |
CN104826130B (zh) * | 2015-02-06 | 2018-06-22 | 中国人民解放军第二军医大学 | Msx3基因特异诱导小胶质细胞选择性极化的方法及其应用 |
CN107530446B (zh) * | 2015-02-27 | 2021-03-05 | 财团法人峨山社会福祉财团 | 含有dpp-4抑制剂的用于预防或治疗瓣膜钙化的组合物 |
JP2018516847A (ja) * | 2015-03-25 | 2018-06-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 生体高分子薬を送達するための組成物及び方法 |
EP4353257A2 (en) | 2015-04-13 | 2024-04-17 | CureVac Manufacturing GmbH | Method for producing rna compositions |
WO2016165831A1 (en) | 2015-04-17 | 2016-10-20 | Curevac Ag | Lyophilization of rna |
SG10201907164SA (en) | 2015-04-22 | 2019-09-27 | Curevac Ag | Rna containing composition for treatment of tumor diseases |
US11384375B2 (en) | 2015-04-30 | 2022-07-12 | Curevac Ag | Immobilized poly(n)polymerase |
DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
AU2016264027A1 (en) | 2015-05-15 | 2017-08-31 | Curevac Ag | Prime-boost regimens involving administration of at least one mRNA construct |
SG10201910431RA (en) | 2015-05-20 | 2020-01-30 | Curevac Ag | Dry powder composition comprising long-chain rna |
US10729654B2 (en) | 2015-05-20 | 2020-08-04 | Curevac Ag | Dry powder composition comprising long-chain RNA |
WO2016193206A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
EP4098743A1 (en) | 2015-05-29 | 2022-12-07 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
EP3650033B1 (en) | 2015-06-15 | 2022-02-16 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
HUE045754T2 (hu) | 2015-06-15 | 2020-01-28 | 4D Pharma Res Ltd | Blautia stercosis és wexlerae gyulladásos és autoimmun betegségek kezelésében történõ alkalmazásra |
MD3307288T2 (ro) | 2015-06-15 | 2019-12-31 | 4D Pharma Res Ltd | Compoziții care conțin tulpini bacteriene |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
US20180296663A1 (en) * | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
CN105087647B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 一种携带Survivin抗原基因的重组腺相关病毒载体及其构建方法与应用 |
CN105087648B (zh) * | 2015-06-17 | 2018-05-25 | 深圳益世康宁生物科技有限公司 | 携带mage-a3抗原基因的重组腺相关病毒载体及构建方法与应用 |
CN105969804B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 一种携带scc抗原基因的重组腺相关病毒载体及其构建方法与应用 |
IL283545B2 (en) | 2015-06-29 | 2023-09-01 | Acuitas Therapeutics Inc | Lipids and nanoparticulate lipid formulations for delivery of nucleic acids |
US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
EP3324979B1 (en) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Infectious disease vaccines |
US20180237786A1 (en) | 2015-08-28 | 2018-08-23 | Curevac Ag | Artificial nucleic acid molecules |
ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
EP3362460A1 (en) | 2015-10-16 | 2018-08-22 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
SI3362461T1 (sl) | 2015-10-16 | 2022-05-31 | Modernatx, Inc. | Analogi kape MRNA z modificirano fosfatno povezavo |
JP2018531290A (ja) | 2015-10-22 | 2018-10-25 | モデルナティーエックス, インコーポレイテッド | 性感染症ワクチン |
JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
JP6925688B2 (ja) | 2015-10-22 | 2021-08-25 | モデルナティーエックス, インコーポレイテッド | 水痘帯状疱疹ウイルス(vzv)のための核酸ワクチン |
DK3718565T3 (da) | 2015-10-22 | 2022-06-20 | Modernatx Inc | Vacciner mod respiratorisk virus |
HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
US11413346B2 (en) | 2015-11-09 | 2022-08-16 | Curevac Ag | Rotavirus vaccines |
TWI797067B (zh) | 2015-11-20 | 2023-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
EP3319622B1 (en) | 2015-12-22 | 2020-02-12 | CureVac AG | Method for producing rna molecule compositions |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
EP3416683A1 (en) | 2016-02-17 | 2018-12-26 | CureVac AG | Zika virus vaccine |
EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
CN114712405A (zh) | 2016-03-04 | 2022-07-08 | 4D制药有限公司 | 包含细菌菌株的组合物 |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
CN109072223B (zh) | 2016-04-08 | 2022-10-21 | 川斯勒佰尔公司 | 多聚体编码核酸及其用途 |
US20190343942A1 (en) | 2016-04-22 | 2019-11-14 | Curevac Ag | Rna encoding a tumor antigen |
US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
US20210162037A1 (en) * | 2016-05-04 | 2021-06-03 | Curevac Ag | Influenza mrna vaccines |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
CN107475355A (zh) * | 2016-06-08 | 2017-12-15 | 益善生物技术股份有限公司 | 肺癌早期筛查试剂盒 |
BR112018075479A2 (pt) | 2016-06-09 | 2019-03-19 | Curevac Ag | portadores híbridos para carga de ácido nucleico |
WO2017218524A1 (en) | 2016-06-13 | 2017-12-21 | Rana Therapeutics, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
AU2017286606A1 (en) | 2016-06-14 | 2018-12-13 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
CN114176043B (zh) * | 2016-06-14 | 2024-04-23 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
CN105994197A (zh) * | 2016-06-16 | 2016-10-12 | 嵊泗县景晟贻贝产业发展有限公司 | 厚壳贻贝剥落机 |
EP3472193A4 (en) * | 2016-06-20 | 2020-01-08 | The Board of Trustees of the Leland Stanford Junior University | CIRCULAR RNA AND THEIR USE IN IMMUNO MODULATION |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
CN109715205A (zh) | 2016-08-19 | 2019-05-03 | 库瑞瓦格股份公司 | 用于癌症治疗的rna |
WO2018041921A1 (en) | 2016-08-31 | 2018-03-08 | Curevac Ag | Mixing device for the production of a liquid nucleic acid composition |
JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
BR112019008369A2 (pt) * | 2016-10-26 | 2019-10-01 | Modernatx Inc | ácidos ribonucleicos mensageiros para intensificar respostas imunes e métodos para uso dos mesmos |
EP3532094A1 (en) | 2016-10-26 | 2019-09-04 | CureVac AG | Lipid nanoparticle mrna vaccines |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
JP2020501545A (ja) | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | 肝疾患の処置または予防のためのrna |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11524066B2 (en) | 2016-12-23 | 2022-12-13 | CureVac SE | Henipavirus vaccine |
US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
EP3558354A1 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Lassa virus vaccine |
CN110168090B (zh) | 2016-12-27 | 2023-07-18 | 国立大学法人东京大学 | mRNA的功能化方法 |
US11382964B2 (en) * | 2017-01-27 | 2022-07-12 | The Methodist Hospital | Core/shell structure platform for immunotherapy |
MA47401A (fr) * | 2017-02-01 | 2021-05-05 | Modernatx Inc | Vaccins anticancéreux à arn |
CN110430894A (zh) | 2017-02-01 | 2019-11-08 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
US11253605B2 (en) | 2017-02-27 | 2022-02-22 | Translate Bio, Inc. | Codon-optimized CFTR MRNA |
BR112019017743A2 (pt) | 2017-02-28 | 2020-04-07 | Sanofi Sa | rna terapêutico |
WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
EP3609534A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS |
WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
US20200085944A1 (en) | 2017-03-17 | 2020-03-19 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
SG11201906297QA (en) | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
CN110636854A (zh) | 2017-03-31 | 2019-12-31 | 阿卡尼斯生物技术F&E有限责任两合公司 | 非黑素瘤皮肤癌(nmsc)的预防和治疗 |
US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
AU2018258575A1 (en) | 2017-04-27 | 2019-11-07 | The Johns Hopkins University | Hepatitis C virus gene sequences and methods of use therefor |
CN116693411A (zh) | 2017-04-28 | 2023-09-05 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
US11173190B2 (en) | 2017-05-16 | 2021-11-16 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR |
WO2018215758A1 (en) | 2017-05-22 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
CN110719954B (zh) | 2017-05-31 | 2023-12-26 | 奥特吉尼克斯制药公司 | 用于iii型糖原贮积病的治疗剂 |
PT3638271T (pt) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Ltd | Composições contendo estirpes bacterianas |
CA3066561C (en) | 2017-06-14 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus megasphera and uses thereof |
WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
EP3648791A1 (en) | 2017-07-04 | 2020-05-13 | CureVac AG | Novel nucleic acid molecules |
EP3437650A1 (en) | 2017-07-31 | 2019-02-06 | Accanis Biotech F&E GmbH & Co KG | Treatment of local skin hypotrophy conditions |
JP7355731B2 (ja) | 2017-08-16 | 2023-10-03 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤における使用のための脂質 |
US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036638A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR PREPARING MODIFIED RNA |
EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
CN107653313B (zh) * | 2017-09-12 | 2021-07-09 | 首都医科大学附属北京胸科医院 | Retn和klk1在作为结核病检测标志物中的应用 |
EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
CN111511405A (zh) * | 2017-10-16 | 2020-08-07 | 阿迪根有限公司 | 用于细胞内递送mRNA的肽和纳米颗粒 |
MX2020003995A (es) | 2017-10-19 | 2020-07-22 | Curevac Ag | Nuevas moleculas de acido nucleico artificiales. |
CN111511924A (zh) | 2017-11-08 | 2020-08-07 | 库瑞瓦格股份公司 | Rna序列调整 |
WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
AU2018392716A1 (en) | 2017-12-20 | 2020-06-18 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
JP2021511016A (ja) | 2017-12-21 | 2021-05-06 | ベースクリック ゲーエムベーハー | クリック修飾mRNA |
WO2019122371A1 (en) | 2017-12-21 | 2019-06-27 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
BR112020020933A2 (pt) | 2018-04-17 | 2021-04-06 | Curevac Ag | Moléculas de rna de rsv inovadoras e composições para vacinação |
CN108611310A (zh) * | 2018-04-28 | 2018-10-02 | 中国药科大学 | 一种重组Hsp65与STEAP1186-193融合蛋白的基因工程菌的构建 |
CN108714213A (zh) * | 2018-06-04 | 2018-10-30 | 北京工业大学 | 一种自组装的纳米佐剂及由该佐剂形成的纳米疫苗的制备方法与应用 |
WO2020002525A1 (en) | 2018-06-27 | 2020-01-02 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
JP7410135B2 (ja) | 2018-09-19 | 2024-01-09 | モデルナティエックス インコーポレイテッド | 治療薬の細胞内送達のための化合物及び組成物 |
JP2022501367A (ja) | 2018-09-20 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | 脂質ナノ粒子の調製及びその投与方法 |
EP4299750A2 (en) | 2018-12-06 | 2024-01-03 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
WO2020128031A2 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
BR112021014845A2 (pt) | 2019-01-31 | 2021-11-03 | Modernatx Inc | Métodos de preparação de nanopartículas lipídicas |
CN111499758B (zh) * | 2019-01-31 | 2023-01-31 | 中国科学院脑科学与智能技术卓越创新中心 | 筛选人钾离子通道调节剂的方法 |
MX2021009236A (es) | 2019-01-31 | 2021-11-12 | Modernatx Inc | Agitadores vorticiales y metodos, sistemas y aparatos asociados de estos. |
CA3125511A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
CN110241116B (zh) * | 2019-05-21 | 2023-02-07 | 中国医学科学院放射医学研究所 | 一种环状rna及在促进dna损伤修复中的应用 |
WO2020254535A1 (en) | 2019-06-18 | 2020-12-24 | Curevac Ag | Rotavirus mrna vaccine |
CN110305866A (zh) * | 2019-07-09 | 2019-10-08 | 江苏省人民医院(南京医科大学第一附属医院) | 利用Cas9技术构建EFTUD2单等位基因敲除的HepG2.2.15细胞株的方法 |
CN110592033B (zh) * | 2019-07-28 | 2022-04-12 | 中国海洋大学 | 一种牙鲆海豚链球菌pdha1多表位多肽 |
CN110804662B (zh) * | 2019-09-30 | 2021-07-13 | 中山大学 | 一种基于sirt2的表达量筛选抗蓝耳病猪的方法 |
US20230090515A1 (en) | 2019-12-20 | 2023-03-23 | Curevac Ag | Lipid nanoparticles for delivery of nucleic acids |
CN116113430A (zh) | 2020-02-04 | 2023-05-12 | 奎尔法克股份有限公司 | 冠状病毒疫苗 |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
JP2023518739A (ja) | 2020-03-19 | 2023-05-08 | ベースクリック ゲーエムベーハー | ワクチン開発のための修飾mRNA |
EP3964576A1 (en) | 2020-09-04 | 2022-03-09 | baseclick GmbH | Modified mrnas for vaccine development |
JP2021147353A (ja) * | 2020-03-19 | 2021-09-27 | 国立大学法人信州大学 | 組成物、脂質粒子製造用キット、物質送達方法及び検出方法 |
WO2021204179A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
JP2023529522A (ja) | 2020-04-09 | 2023-07-11 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質ナノ粒子組成物 |
JP2023530229A (ja) | 2020-05-29 | 2023-07-14 | キュアバック エスイー | 核酸ベースの混合ワクチン |
US20220331414A1 (en) | 2020-06-30 | 2022-10-20 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
CN111875699B (zh) * | 2020-07-03 | 2022-07-05 | 江南大学 | 一种提高枯草芽孢杆菌卵清蛋白表达量的方法 |
CN111973616A (zh) * | 2020-07-15 | 2020-11-24 | 中山大学 | 副溶血弧菌23S rRNA和/或其保守序列VP13在提高鱼类免疫力中的应用 |
US11976019B2 (en) | 2020-07-16 | 2024-05-07 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
CN111965353B (zh) * | 2020-08-18 | 2022-08-19 | 四川农业大学 | 绵羊痒螨半胱氨酸蛋白酶抑制剂的应用以及一种elisa试剂盒 |
JP2023537887A (ja) | 2020-08-20 | 2023-09-06 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN112011501B (zh) * | 2020-08-26 | 2022-11-08 | 福建省医学科学研究院 | 一种携带c.3369-3370 insC突变的HCM特异性诱导多能干细胞系 |
WO2022043551A2 (en) | 2020-08-31 | 2022-03-03 | Curevac Ag | Multivalent nucleic acid based coronavirus vaccines |
CN112194719A (zh) * | 2020-09-01 | 2021-01-08 | 中日友好医院(中日友好临床医学研究所) | Crt抗原和mage-a1抗原的制备及其应用 |
RU2761876C1 (ru) * | 2020-11-27 | 2021-12-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В.Ломоносова" (МГУ) | Гуманизированное антитело 5d3hu, связывающееся с опухолевым антигеном prame, фрагменты днк, кодирующие указанное антитело и антигенсвязывающий фрагмент антитела |
CN112637884B (zh) * | 2020-12-08 | 2022-09-20 | 广西电网有限责任公司电力科学研究院 | 基于扩张状态观测器的wsn的模型预测控制方法 |
KR20230164648A (ko) | 2020-12-22 | 2023-12-04 | 큐어백 에스이 | SARS-CoV-2 변이체에 대한 RNA 백신 |
WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
CN116615472A (zh) | 2021-01-14 | 2023-08-18 | 苏州艾博生物科技有限公司 | 聚合物缀合的脂质化合物和脂质纳米颗粒组合物 |
EP4087938A2 (en) | 2021-01-27 | 2022-11-16 | CureVac AG | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
KR20220117133A (ko) | 2021-02-15 | 2022-08-23 | 주식회사 바이오파마 | 양이온성 분자 수송체 및 SARS-CoV-2 mRNA의 이온 복합체를 포함하는 코로나바이러스감염증-19 예방 백신 조성물 |
WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
KR20240013087A (ko) | 2021-05-24 | 2024-01-30 | 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 | 지질 화합물 및 지질 나노입자 조성물 |
WO2023006999A2 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Mrnas for treatment or prophylaxis of liver diseases |
AU2022336664A1 (en) | 2021-09-03 | 2024-01-18 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
KR20240049810A (ko) | 2021-09-03 | 2024-04-17 | 큐어백 에스이 | 핵산 전달용 신규 지질 나노입자 |
WO2023034957A1 (en) * | 2021-09-03 | 2023-03-09 | University Of Connecticut | Stabilization of antigens for long term administration in transdermal microneedle patches |
CA3232386A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
CN116064598B (zh) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
AU2022358824A1 (en) | 2021-10-08 | 2024-04-11 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
AR127312A1 (es) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2024015803A2 (en) | 2022-07-11 | 2024-01-18 | Autonomous Therapeutics, Inc. | Encrypted rna and methods of its use |
WO2024020451A2 (en) * | 2022-07-21 | 2024-01-25 | Thomas Jefferson University | Methods and compositions for selectively modulating gene expression in megakaryocytes and platelets |
CN115414494B (zh) * | 2022-08-17 | 2024-04-26 | 南京中医药大学 | 一种多肽类纳米疫苗及其制备方法与应用 |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
KR102624969B1 (ko) * | 2023-04-03 | 2024-01-16 | 한국과학기술원 | mRNA 번역 증가를 유도하는 mRNA 3'UTR 서열 |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3314999A1 (de) | 1983-04-26 | 1985-03-14 | Behringwerke Ag, 3550 Marburg | Verwendung des diterpen-derivates forskolin zur immunstimulation |
US5663163A (en) | 1987-09-07 | 1997-09-02 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds and processes for preparation thereof |
CA1320446C (en) | 1988-06-20 | 1993-07-20 | William A. Carter | Modulation of lymphokine-resistant cellular states by dsrnas |
EP0495919B1 (en) | 1989-10-11 | 1997-01-15 | Hem Pharmaceuticals Corp. | PROTECTION FROM SHOCK SUBSEQUENT TO INJURY BY DOUBLE-STRANDED RNAs |
DK0677056T3 (da) | 1993-01-25 | 1996-08-05 | Hybridon Inc | Oligonukleotid-alkylphosphonater og -alkylphosphonothioater |
WO1994017792A2 (en) | 1993-01-27 | 1994-08-18 | Affymax Technologies N.V. | Compositions and methods for transdermal drug delivery |
US5516652A (en) | 1993-10-06 | 1996-05-14 | Merck Frosst Canada Inc. | DNA encoding prostaglandin receptor IP |
WO1995025814A1 (en) | 1994-03-18 | 1995-09-28 | Lynx Therapeutics, Inc. | Oligonucleotide n3'→p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
JP3468773B2 (ja) | 1994-07-15 | 2003-11-17 | ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫調節オリゴヌクレオチド |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6689757B1 (en) | 1996-02-12 | 2004-02-10 | M.L. Laboratories Plc | Methods for vaccination and vaccines therefor |
US6090391A (en) | 1996-02-23 | 2000-07-18 | Aviron | Recombinant tryptophan mutants of influenza |
AU4992197A (en) | 1996-10-11 | 1998-05-11 | Regents Of The University Of California, The | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO1998047913A2 (en) | 1997-04-18 | 1998-10-29 | The University Of Medicine And Dentistry Of New Jersey | Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US20040006034A1 (en) | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP0986572B2 (en) | 1997-06-06 | 2007-06-13 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1374894A3 (en) | 1997-06-06 | 2004-09-22 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1872786A1 (en) | 1997-09-05 | 2008-01-02 | The Regents of the University of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
US6096307A (en) | 1997-12-11 | 2000-08-01 | A. Glenn Braswell | Compositions for immunostimulation containing Echinacea angustofolia, bromelain, and lysozyme |
EP1067956B1 (en) | 1998-04-03 | 2007-03-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
WO1999053961A1 (en) | 1998-04-23 | 1999-10-28 | The Regents Of The University Of Michigan | Peptides for efficient gene transfer |
US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
WO2000049158A2 (en) | 1999-02-18 | 2000-08-24 | Compugen Ltd. | Psa and klk-2 splicing variants |
CA2376634A1 (en) | 1999-06-08 | 2000-12-14 | Aventis Pasteur | Immunostimulant oligonucleotide |
US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
WO2001004135A2 (en) | 1999-07-13 | 2001-01-18 | The Regents Of The University Of Michigan | Crosslinked dna condensate compositions and gene delivery methods |
JP2003504080A (ja) | 1999-07-13 | 2003-02-04 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
DE69943068D1 (de) * | 1999-09-09 | 2011-02-03 | Curevac Gmbh | Transfer von mRNA unter Verwendung von polykationischen Verbindungen |
ES2340249T3 (es) | 1999-12-06 | 2010-06-01 | Agensys, Inc. | Antigenos transmembrana de tipo serpentina expresados en canceres de prostata humanos y sus usos. |
WO2001055341A2 (en) | 2000-01-31 | 2001-08-02 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
PT2796553T (pt) | 2000-03-30 | 2019-09-27 | Massachusetts Inst Technology | Mediadores de interferência de arn específicos de sequência de arn |
EP1292331A2 (en) | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
CA2410371C (en) | 2000-06-22 | 2015-11-17 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
ES2273852T3 (es) | 2000-06-23 | 2007-05-16 | Wyeth Holdings Corporation | Proteinas v de morbillivirus modificadas. |
US6376704B1 (en) | 2000-06-28 | 2002-04-23 | 3M Innovative Properties Company | Naphthyoxyalkyl(meth)acrylates with high refractive indices and low glass transition temperatures |
US6716434B1 (en) | 2000-09-19 | 2004-04-06 | Daniel R. Ansley | Composition and method for immunostimulation in non- mammalian vertebrates |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
WO2002078614A2 (en) | 2001-04-02 | 2002-10-10 | University Of South Florida | Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof |
EP1832603B1 (de) * | 2001-06-05 | 2010-02-03 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung |
US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
DE10148886A1 (de) | 2001-10-04 | 2003-04-30 | Avontec Gmbh | Inhibition von STAT-1 |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
DE10162480A1 (de) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
WO2003056280A1 (de) | 2001-12-31 | 2003-07-10 | Asm Automation Sensorik Messtechnik Gmbh | Magnetostriktives sensor-element |
WO2003059381A2 (en) | 2002-01-18 | 2003-07-24 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
KR100468534B1 (ko) | 2002-01-31 | 2005-01-27 | 주식회사 엑스넷 | 무선 통신을 이용한 실시간 컨벤션 이벤트 관리시스템 |
ES2339934T3 (es) | 2002-03-01 | 2010-05-27 | The Administrators Of The Tulane Educational Fund | Conjugados de agentes citotoxicos y peptidos biologicamente activos. |
US8153141B2 (en) | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
PT1511768E (pt) | 2002-06-11 | 2007-07-16 | Glaxo Group Ltd | Composições imunogénicas |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
EP1393745A1 (en) | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends |
WO2004016643A2 (en) | 2002-08-16 | 2004-02-26 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
WO2004058159A2 (en) | 2002-12-23 | 2004-07-15 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
CA2512484A1 (en) | 2003-01-16 | 2004-05-08 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
EP1587837B1 (en) | 2003-01-28 | 2012-06-13 | Proscan RX Pharma Inc. | Epitope sequences for prostate cancer diagnosis and treatment |
US20040242502A1 (en) | 2003-04-08 | 2004-12-02 | Galenica Pharmaceuticals, Inc. | Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines |
JP2007514644A (ja) | 2003-04-10 | 2007-06-07 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫反応を向上させる方法および組成物 |
CA2530613A1 (en) | 2003-06-30 | 2005-01-06 | Universite De Lausanne | Rasgap derived peptide for selectively killing cancer cells |
WO2005030800A2 (en) | 2003-08-05 | 2005-04-07 | Avi Biopharma, Inc. | Oligonucleotide analog and method for treating flavivirus infections |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
US7615539B2 (en) | 2003-09-25 | 2009-11-10 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
DE10346721A1 (de) | 2003-10-08 | 2005-05-04 | Holger Kalthoff | Oligonukleotide, diese enthaltende Mittel und deren Verwendung |
KR101138131B1 (ko) | 2003-12-08 | 2012-04-23 | 이데라 파마슈티칼즈, 인코포레이티드 | 작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절 |
EP2415481A3 (en) | 2004-02-19 | 2012-04-18 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral RNA oligonucleotides |
EP1742966B1 (en) | 2004-04-22 | 2013-11-27 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to steap-1 proteins |
WO2006046978A2 (en) | 2004-06-28 | 2006-05-04 | Argos Therapeutics, Inc. | Cationic peptide-mediated transformation |
DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
WO2006029223A2 (en) | 2004-09-08 | 2006-03-16 | Children's Medical Center Corporation | Method for stimulating the immune response of newborns |
CN101142516B (zh) | 2005-03-14 | 2011-08-24 | 富士通株式会社 | 液晶显示装置和液晶显示装置的制造方法 |
AU2006241566B2 (en) | 2005-05-04 | 2010-12-16 | Single Buoy Moorings Inc. | Large distance offshore LNG export terminal with boil-off vapour collection and utilization capacities |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
MX2008003076A (es) | 2005-09-02 | 2008-03-19 | Procter & Gamble | Indicador eficaz de la salud del cuero cabelludo. |
WO2007031322A1 (en) | 2005-09-14 | 2007-03-22 | Gunther Hartmann | Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides |
EP1764107A1 (en) | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides |
BRPI0616211A2 (pt) | 2005-09-19 | 2011-06-14 | Veridex Llc | mÉtodos para o diagnàstico de cÂncer pancreÁtico |
JP2009511034A (ja) | 2005-10-12 | 2009-03-19 | キャンサー・リサーチ・テクノロジー・リミテッド | 免疫異常を治療するための方法および組成物 |
CA2628300C (en) | 2005-11-02 | 2018-04-17 | Protiva Biotherapeutics, Inc. | Modified sirna molecules and uses thereof |
US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
EP1968643A2 (en) | 2005-12-16 | 2008-09-17 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids into a cell |
DE102006007433A1 (de) * | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
EP2027158B1 (en) | 2006-05-02 | 2012-09-19 | Carviar ApS | Method for immunizing an avian species |
AU2007280690C1 (en) * | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
DE102006035618A1 (de) * | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
AU2007286059A1 (en) | 2006-08-18 | 2008-02-21 | Mdrna, Inc. | Dicer substrate RNA peptide conjugates and methods for RNA therapeutics |
US20080071711A1 (en) | 2006-09-20 | 2008-03-20 | Siemens Corporate Research, Inc. | Method and System for Object Detection Using Probabilistic Boosting Cascade Tree |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046738A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009053700A1 (en) | 2007-10-23 | 2009-04-30 | Cancer Research Technology Limited | Modification of nucleic acid-containing biological entities |
WO2009086640A1 (en) | 2008-01-10 | 2009-07-16 | Nventa Biopharmaceuticals Corporation | Adjuvant compositions comprising poly-ic and a cationic polymer |
EP2548960B1 (en) | 2008-01-31 | 2018-01-31 | CureVac AG | Nucleic acids comprising formula (nugixmgnv)a and derivatives thereof as an immunostimulating agents/adjuvant |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
-
2008
- 2008-09-30 WO PCT/EP2008/008304 patent/WO2010037408A1/en active Application Filing
-
2009
- 2009-09-30 AU AU2009300113A patent/AU2009300113B2/en not_active Ceased
- 2009-09-30 EP EP13005251.7A patent/EP2762165B1/en not_active Not-in-force
- 2009-09-30 BR BRPI0915844-8A patent/BRPI0915844B1/pt not_active IP Right Cessation
- 2009-09-30 RU RU2011116931/15A patent/RU2545756C2/ru active
- 2009-09-30 ES ES09736823.7T patent/ES2502915T3/es active Active
- 2009-09-30 JP JP2011526423A patent/JP5859853B2/ja not_active Expired - Fee Related
- 2009-09-30 CA CA2730261A patent/CA2730261C/en not_active Expired - Fee Related
- 2009-09-30 SI SI200930990T patent/SI2331129T1/sl unknown
- 2009-09-30 US US12/994,407 patent/US9572874B2/en active Active
- 2009-09-30 EP EP09736823.7A patent/EP2331129B1/en active Active
- 2009-09-30 PL PL09736823T patent/PL2331129T3/pl unknown
- 2009-09-30 CN CN200980131936.5A patent/CN102123733B/zh not_active Expired - Fee Related
- 2009-09-30 MX MX2010013071A patent/MX2010013071A/es active IP Right Grant
- 2009-09-30 PT PT97368237T patent/PT2331129E/pt unknown
- 2009-09-30 WO PCT/EP2009/007032 patent/WO2010037539A1/en active Application Filing
- 2009-09-30 KR KR1020117001541A patent/KR101343043B1/ko active IP Right Grant
- 2009-09-30 DK DK09736823.7T patent/DK2331129T3/da active
-
2014
- 2014-05-07 JP JP2014096387A patent/JP5931120B2/ja not_active Expired - Fee Related
- 2014-08-12 HR HRP20140763AT patent/HRP20140763T1/hr unknown
-
2017
- 2017-01-17 US US15/408,339 patent/US20170202957A1/en not_active Abandoned
-
2020
- 2020-06-19 US US16/907,130 patent/US20210046179A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2331129T3 (da) | Sammensætning omfattende et kompleksbundet (m)rna og et nøgen mrna for at tilvejebringe eller øge et immunstimulerende respons i et pattedyr og anvendelser deraf | |
DK2195450T3 (da) | Fremgangsmåder til anvendelse af mirna til detektion af in vivo celledød | |
FI20075613A0 (fi) | Sovitelma ja menetelmä kuormitusvasteen parantamiseksi aluksessa | |
EP2419538A4 (en) | METHODS AND COMPOSITIONS FOR DETECTING AND DIFFERENTIATING SMALL RNA IN AN RNA MATURATION PATH | |
DK2252633T3 (da) | Anti-TrkA antistoffer og derivater deraf | |
DK2125069T3 (da) | Indretning til stof- og eller energiudveksling | |
DOP2010000260A (es) | Derivado heterociclico fusionado y su uso | |
DK3381638T3 (da) | Forbedringer i eller i relation til et formgivningsapparat | |
EP2132334A4 (en) | METHODS AND COMPOSITIONS ASSOCIATED WITH DETECTION OF NUCLEIC ACIDS | |
DK2337837T3 (da) | Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf | |
DK2089524T3 (da) | DNase ekspression i rekombinante værtsceller | |
EP2069929A4 (en) | PERFORMANCE-BASED TEST SYSTEM AND METHOD USING EMULATION AND VIRTUALIZATION | |
DK2616709T3 (da) | Forbedringer i eller relateret til fastspændingselementer og fastspændingsindretninger. | |
DK2410499T3 (da) | Spille- og/eller underholdningsanordning | |
BRPI0919411A2 (pt) | derivado de glicosídeo e usos dos mesmos | |
GB0620114D0 (en) | Improvements in or relating to turbochargers | |
DK2288707T3 (da) | Eukaryot sekretionssignalsekvens til rekombinant ekspression i prokaryoter | |
DK2069494T3 (da) | Cellulase-frie enzymsammensætninger og værtsceller til fremstilling heraf | |
EP2001459A4 (en) | METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO HIV AND MODELS FOR TESTING | |
GB2449179B (en) | Improvements in and relating to cladding | |
DK2358585T3 (da) | Forbedring i eller i forbindelse med flydeanordninger | |
GB0705482D0 (en) | Improvements in and relating to stress | |
DK2324893T3 (da) | Skrabespilsystem og tilsvarende spillemedium | |
GB2497495B (en) | Compositions, methods and kits to detect adenovirus nucleic acids | |
GB2453536B (en) | Improvements in or relating to handling test rigs |